Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study

Volume 72, Issue 6 June 2017 

• 1. 
     Previous article in issue: Overview of systematic reviews in allergy epidemiology
• 
  
• Abstract
  Background

  The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients’ lives. It is freely available in 20 countries (iOS and Android platforms).
  Aims

  
  

  To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diarycould be identified and (iii) information gathered by this study could suggest novel research questions.
  Methods

  The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1–2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms.

Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Allergy, Asthma & Clinical Immunology

RESEARCH  

OPEN ACCESS

• Paul RatnerEmail author,
• Charles P. Andrews,
• Frank C. Hampel,
• Bruce Martin,
• Dale E. Mohar,
• Denis Bourrelly,
• Parisa Danaietash,
• Sara Mangialaio,
• Jasper Dingemanse,
• Abdel Hmissi and
• Jay van Bavel

Allergy, Asthma & Clinical Immunology201713:18

DOI: 10.1186/s13223-017-0183-z

Abstract

Background

Antagonism of chemoattractant receptor-homologous molecule on T-helper type-2 cells (CRTH2), a G-protein coupled receptor for prostaglandin D2, could be beneficial for treating allergic disorders. We present findings on the efficacy and safety/tolerability of a CRTH2 antagonist (setipiprant) in participants with seasonal allergic rhinitis (AR) in a real-life setting over 2 weeks.

Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study

Clinical and Molecular Allergy

RESEARCH

 

OPEN ACCESS

• I. Djuric-Filipovic,
• Marco CaminatiEmail author,
• D. Filipovic,
• C. Salvottini and
• Z. Zivkovic

Clinical and Molecular Allergy201715:7

DOI: 10.1186/s12948-017-0064-5

Abstract

Background

Allergen-specific immunotherapy (AIT) is the only treatment able to change the natural course of allergic diseases. We aimed at investigating the clinical efficacy of SLITOR (Serbian registered vaccine for sublingual allergen specific immunotherapy).